JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACYVolume 6, Issue 6 p. 657-662 PSAP IN JACCP Part I: Interactive case: Menopause Nicole E. Cieri-Hutcherson Pharm.D., Nicole E. Cieri-Hutcherson Pharm.D. orcid.org/0000-0002-2861-3074 Search for more papers by this authorVeronica Vernon Pharm.D., Veronica Vernon Pharm.D. orcid.org/0000-0002-5638-3851 Search for more papers by this author Nicole E. Cieri-Hutcherson Pharm.D., Nicole E. Cieri-Hutcherson Pharm.D. orcid.org/0000-0002-2861-3074 Search for more papers by this authorVeronica Vernon Pharm.D., Veronica Vernon Pharm.D. orcid.org/0000-0002-5638-3851 Search for more papers by this author First published: 07 June 2023 https://doi.org/10.1002/jac5.1814Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES American College of Obstetricians and Gynecologists' Committee on Clinical Consensus – Gynecology (ACOG). Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: clinical consensus. Obstet Gynecol. 2021; 138: 950– 60. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice, American Society for Reproductive Medicine Practice Committee (ACOG). Committee Opinion 532: compounded bioidentical menopausal hormone therapy. Obstet Gynecol. 2012; 120: 411– 5. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004; 291: 1701– 12. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015; 175: 531– 9. Bassuk SS, Manson JE. Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes. Ann Epidemiol. 2015; 25: 193– 200. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2020; 26(suppl 1): 1– 46. Clark K, Westberg SM. Benefits of levonorgestrel intrauterine device use vs. oral or transdermal progesterone for postmenopausal women using estrogen containing hormone therapy. Innov Pharm. 2019; 10: 7. https://doi.org/10.24926/iip.v10i3.200 Cobin RH, Goodman NF, AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause – 2017 update. Endocr Pract. 2017; 23(23): 869– 80. Constantine GD, Goldstein SR, Archer DF. Endometrial safety of ospemifene: results of the phase 2/3 clinical development program. Menopause. 2015; 22: 36– 43. CJ Crandall, editor. Menopause practice: a clinician's guide. 6th ed. North American Menopause Society; 2019. Depypere H, Timmerman D, Donders G, et al. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial. J Clin Endocrinol Metab. 2019; 104: 5893– 905. Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019; 104: 1595– 622. Endocrine Society. Position statement: compounded bioidentical hormone. 2019. Ettinger B, Wang SM, Leslie RS, et al. Evolution of postmenopausal hormone therapy between 2002 and 2009. Menopause. 2018; 25: 1306– 12. Flores VA, Pal L, Manson JE. Hormone therapy in menopause: concepts, controversies, and approach to treatment. Endocr Rev. 2021; 42: 720– 52. Fraser GL, Lederman S, Waldbaum A, et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020; 27: 389– 92. Hays J, Hunt JR, Hubbell FA, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol. 2003; 13: S18– 77. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011; 305: 1305– 14. LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022; 33: 2049– 102. Manson JE, Aragaki AK, Bassuk SS, et al. Menopausal estrogen-alone therapy and health outcomes in women with and without bilateral oophorectomy: a randomized trial. Ann Intern Med. 2019; 171: 406– 14. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017; 318: 927– 38. Manson JE, Bassuk SS, Kaunitz AM, et al. The Women's Health Initiative trials of menopausal hormone therapy: lessons learned. Menopause. 2020; 27: 918– 28. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013; 310: 1353– 68. Mehta J, Kling JM, Manson JE. Risks, benefits, and treatment modalities of menopausal hormone therapy: current concepts. Front Endocrinol (Lausanne). 2021; 12:564781. National Academies of Sciences, Engineering, and Medicine (NASEM). The clinical utility of compounded bioidentical hormone therapy: a review of safety, effectiveness, and use. National Academies Press; 2020. North American Menopause Society (NAMS). Isoflavones report. The role of soy isoflavones in menopausal health: report of the North American Menopause Society. Menopause. 2011; 18: 732– 53. North American Menopause Society (NAMS). Hormone Therapy Position Statement Advisory Panel. The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society. Menopause. 2020; 2020(27): 976– 92. North American Menopause Society (NAMS). Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause. 2021;(17): 25– 54. North American Menopause Society (NAMS). Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of the North American Menopause Society. Menopause. 2022; 2022(29): 767– 94. North American Menopause Society-A (NAMSa). Use of compounded hormone therapy in the United States: report of The North American Menopause Society Survey. Menopause. 2015; 22: 1276– 84. North American Menopause Society-B (NAMSb). Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015; 28: 973– 97. Prague JK, Roberts RE, Comninos AN, et al. Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action. Menopause. 2018; 25: 862– 9. Qaseem A, Forciea MA, McLean RM, et al. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017; 166: 818– 39. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321– 33. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297: 1465– 77. Sahni S, Lobo-Romero A, Smith T. Contemporary non-hormonal therapies for the management of vasomotor symptoms associated with menopause: a literature review. TouchREV Endocrinol. 2021; 17: 133– 7. Shifren JL, Crandall CJ, Manson JE. Menopausal hormone therapy. JAMA. 2019; 321: 2458– 9. Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab. 2020; 105: 587– 94. Simon J, Anderson RA, Ballantyne E, et al. OR11-03 NT-814, a non-hormonal dual neurokinin 1,3 receptor antagonist markedly improves vasomotor symptoms in post-menopausal women; results of a randomised, double-blind, placebo- controlled, dose-finding study (SWITCH-1). J Endocr Soc. 2020; 4(suppl 1):OR11-03. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015; 100: 3975– 4011. Szeliga A, Czyzyk A, Podfigurna A, et al. The role of kisspeptin/neurokinin B/dynorphin neurons in pathomechanism of vasomotor symptoms in postmenopausal women: from physiology to potential therapeutic applications. Gynecol Endocrinol. 2018; 34: 913– 9. Whiteley J, DiBonaventura MD, Wagner JS, et al. The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. J Womens Health. 2013; 22: 983– 90. Wild RA, Hovey KM, Andrews C, et al. Cardiovascular disease (CVD) risk scores, age, or years since menopause to predict cardiovascular disease in the Women's Health Initiative. Menopause. 2021; 28: 610– 8. Zernig G, Lechner T, Kramer-Reinstadler K, et al. What the clinician still has to be reminded of. Ther Drug Monit. 2004; 26: 582. Zhang L, Brown SJ, Shan Y, et al. CYP2D6 genetic polymorphisms and risperidone pharmacokinetics: a systematic review and meta-analysis. Pharmacotherapy. 2020; 40: 632– 47. Zierhut HA, Campbell CA, Mitchell AG, et al. Collaborative counseling considerations for pharmacogenomic tests. Pharmacotherapy. 2017; 37: 990– 9. Volume6, Issue6June 2023Pages 657-662 ReferencesRelatedInformation